Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ocugen ( (OCGN) ) has shared an update.
On January 15, 2026, Ocugen reported positive preliminary 12‑month data from its Phase 1 and Phase 2 ArMaDa trials of OCU410, an AAV5-based modifier gene therapy for geographic atrophy secondary to dry age-related macular degeneration, a condition affecting millions worldwide and poorly served by existing treatments. In the Phase 2 trial, about half of enrolled patients evaluated at 12 months showed a 46% reduction in lesion growth versus control across medium and high doses, with the medium dose alone achieving a 54% reduction and no OCU410-related serious adverse events observed, while Phase 1 data indicated 60% slower ellipsoid zone loss and preservation of photoreceptors and retinal pigment epithelium, underscoring a potentially favorable risk-benefit profile and positioning OCU410 as a prospective one-time alternative to chronic injection-based therapies as Ocugen advances toward later-stage development and eventual regulatory filings.
The most recent analyst rating on (OCGN) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page.
Spark’s Take on OCGN Stock
According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral.
Score is held back primarily by weak financial performance (ongoing losses, very high leverage, and challenged cash flow). Offsetting factors include a strong technical uptrend with positive MACD (though momentum is overbought) and an earnings call that emphasized meaningful clinical/program progress and extended runway, while valuation remains difficult to support due to negative earnings and no dividend.
To see Spark’s full report on OCGN stock, click here.
More about Ocugen
Ocugen, Inc. is a biotechnology company specializing in the discovery, development, and commercialization of novel gene therapies for major blindness diseases, leveraging a gene-agnostic modifier gene therapy platform aimed at large patient populations with significant unmet medical need in conditions such as dry age-related macular degeneration and geographic atrophy.
Average Trading Volume: 3,949,177
Technical Sentiment Signal: Buy
Current Market Cap: $587.2M
For detailed information about OCGN stock, go to TipRanks’ Stock Analysis page.